The hypoxia-inducible factor pathway in adipocytes: The role of HIF-2 in adipose inflammation and hypertrophic cardiomyopathy

Frontiers in Endocrinology

Volumn 6, Issue MAR, 2015, Pages

  Lin, Qun ^a   Yun, Zhong ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adipocyte; Cardiomyopathy; Heart; HIF 2; Hypertrophy; Hypoxia; Obesity; Von Hippel Lindau

Indexed keywords

ADIPONECTIN; AMINO ACID; FAT; FATTY ACID BINDING PROTEIN 4; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; VON HIPPEL LINDAU PROTEIN;

ADIPOCYTE; ADIPOGENESIS; CARDIOMEGALY; CARDIOVASCULAR DISEASE; GENE DELETION; GENE OVEREXPRESSION; GLUCOSE INTOLERANCE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; NONHUMAN; OBESITY; OXYGEN TENSION; PHENOTYPE; REVIEW;

EID: 84926628423     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00039     Document Type: Review

References (63)

1. Cotillard A, Poitou C, Torcivia A, Bouillot JL, Dietrich A, Kloting N, et al. Adipocyte size threshold matters: link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab (2014) 99:E1466-70. doi: 10.1210/jc.2014-1074
2. Salans LB, Knittle JL, Hirsch J. The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity. J Clin Invest (1968) 47:153-65. doi:10.1172/JCI105705
3. Stern JS, Batchelor BR, Hollander N, Cohn CK, Hirsch J. Adipose-cell size and immunoreactive insulin levels in obese and normal-weight adults. Lancet (1972) 2:948-51. doi:10.1016/S0140-6736(72)92474-9
4. Ye J. Adipose tissue vascularization: its role in chronic inflammation. Curr Diab Rep (2011) 11:203-10. doi:10.1007/s11892-011-0183-1
5. Trayhurn P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. Annu Rev Nutr (2014) 34:207-36. doi:10.1146/annurev-nutr-071812-161156
6. Lee YS, Kim JW, Osborne O, Oh da Y, Sasik R, Schenk S, et al. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. Cell (2014) 157:1339-52. doi:10.1016/j.cell.2014.05.012
7. Ye J, Gao Z, Yin J, He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab (2007) 293:E1118-28. doi:10.1152/ajpendo.00435.2007
8. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) (2008) 32:451-63. doi:10.1038/sj.ijo.0803744
9. Sun K, Halberg N, Khan M, Magalang UJ, Scherer PE. Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue dysfunction. Mol Cell Biol (2013) 33:904-17. doi:10.1128/MCB.00951-12
10. Pasarica M, Sereda OR, Redman LM, Albarado DC, Hymel DT, Roan LE, et al. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes (2009) 58:718-25. doi:10.2337/db08-1098
11. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, et al. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. Circulation (2011) 124:67-76. doi:10.1161/CIRCULATIONAHA.111.027813
12. Hodson L, Humphreys SM, Karpe F, Frayn KN. Metabolic signatures of human adipose tissue hypoxia in obesity. Diabetes (2013) 62:1417-25. doi:10.2337/db12-1032
13. Hodson L. Adipose tissue oxygenation: effects on metabolic function. Adipocyte (2014) 3:75-80. doi:10.4161/adip.27114
14. Lin Q, Lee YJ, Yun Z. Differentiation arrest by hypoxia. J Biol Chem (2006) 281:30678-83. doi:10.1074/jbc.C600120200
15. Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition of PPARγ2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell (2002) 2:331-41. doi:10.1016/S1534-5807(02)00131-4
16. Arner E, Westermark PO, Spalding KL, Britton T, Ryden M, Frisen J, et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes (2010) 59:105-9. doi:10.2337/db09-0942
17. Lin Q, Huang Y, Booth CJ, Haase VH, Johnson RS, Celeste Simon M, et al. Activation of hypoxia-inducible factor-2 in adipocytes results in pathological cardiac hypertrophy. J Am Heart Assoc (2013) 2:e000548. doi:10.1161/JAHA.113.000548
18. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol (1999) 15:551-78. doi:10.1146/annurev.cellbio.15.1.551
19. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev (2003) 17:2614-23. doi:10.1101/gad.1145503
20. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell (2001) 107:43-54. doi:10.1016/S0092-8674(01)00507-4
21. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFa targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science (2001) 292:464-8. doi:10.1126/science.1059817
22. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-a to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 292:468-72. doi:10.1126/science.1059796
23. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem (2004) 279:38458-65. doi:10.1074/jbc.M406026200
24. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J (2003) 22:4082-90. doi:10.1093/emboj/cdg392
25. Kim W, Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev (2003) 13:55-60. doi:10.1016/S0959-437X(02)00010-2
26. Aragones J, Fraisl P, Baes M, Carmeliet P. Oxygen sensors at the crossroad of metabolism. Cell Metab (2009) 9:11-22. doi:10.1016/j.cmet.2008.10.001
27. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, et al. Hypoxia-inducible factor 1a induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol (2009) 29:4467-83. doi:10.1128/MCB.00192-09
28. Shimba S, Wada T, Hara S, Tezuka M. EPAS1 promotes adipose differentiation in 3T3-L1 cells. J Biol Chem (2004) 279:40946-53. doi:10.1074/jbc.M400840200
29. Girgis CM, Cheng K, Scott CH, Gunton JE. Novel links between HIFs, type 2 diabetes, and metabolic syndrome. Trends Endocrinol Metab (2012) 23:372-80. doi:10.1016/j.tem.2012.05.003
30. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest (1999) 103:691-6. doi:10.1172/JCI5912
31. Zhang H, Zhang G, Gonzalez FJ, Park SM, Cai D. Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol (2011) 9:e1001112. doi:10.1371/journal.pbio.1001112
32. Rahtu-Korpela L, Karsikas S, Horkko S, Sequeiros RB, Lammentausta E, Makela KA, et al. HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. Diabetes (2014) 63(10):3324-33. doi:10.2337/db14-0472
33. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A (2003) 100:15712-7. doi:10.1073/pnas.2536828100
34. Abel ED, Peroni O, Kim JK, Kim YB, Boss O, Hadro E, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature (2001) 409:729-33. doi:10.1038/35055575
35. Zhang J, Wang Y, Gao Z, Yun Z, Ye J. Hypoxia-inducible factor 1 activation from adipose protein 2-cre mediated knockout of von Hippel-Lindau gene leads to embryonic lethality. Clin Exp Pharmacol Physiol (2012) 39:145-50. doi:10.1111/j.1440-1681.2011.05656.x
36. Martens K, Bottelbergs A, Baes M. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Lett (2010) 584:1054-8. doi:10.1016/j.febslet.2010.01.061
37. Liu J, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis. A glycogen synthase kinase 3beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem (2004) 279:45020-7. doi:10.1074/jbc.M407050200
38. Gustafson B, Jack MM, Cushman SW, Smith U. Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun (2003) 308:933-9. doi:10.1016/S0006-291X(03)01518-3
39. Korner A, Wabitsch M, Seidel B, Fischer-Posovszky P, Berthold A, Stumvoll M, et al. Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun (2005) 337:540-50. doi:10.1016/j.bbrc.2005.09.064
40. Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W, Gavrilova O, et al. Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes (2011) 60(10):2484-95. doi:10.2337/db11-0174
41. Lee KY, Gesta S, Boucher J, Wang XL, Kahn CR. The differential role of Hif1β/Arnt and the hypoxic response in adipose function, fibrosis, and inflammation. Cell Metab (2011) 14:491-503. doi:10.1016/j.cmet.2011.08.006
42. Beischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr (2008) 18:207-50. doi:10.1615/CritRevEukarGeneExpr.v18.i3.20
43. Bersten DC, Sullivan AE, Peet DJ, Whitelaw ML. bHLH-PAS proteins in cancer. Nat Rev Cancer (2013) 13:827-41. doi:10.1038/nrc3621
44. Kihira Y, Miyake M, Hirata M, Hoshina Y, Kato K, Shirakawa H, et al. Deletion of hypoxia-inducible factor-1alpha in adipocytes enhances glucagon-like peptide-1 secretion and reduces adipose tissue inflammation. PLoS One (2014) 9:e93856. doi:10.1371/journal.pone.0093856
45. Zhang X, Lam KS, Ye H, Chung SK, Zhou M, Wang Y, et al. Adipose tissue-specific inhibition of hypoxia-inducible factor 1a induces obesity and glucose intolerance by impeding energy expenditure in mice. J Biol Chem (2010) 285:32869-77. doi:10.1074/jbc.M110.135509
46. Matsuura H, Ichiki T, Inoue E, Nomura M, Miyazaki R, Hashimoto T, et al. Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance. Circulation (2013) 127:2078-87. doi:10.1161/CIRCULATIONAHA.113.001742
47. Michailidou Z, Morton NM, Moreno Navarrete JM, West CC, Stewart KJ, Fernandez-Real JM, et al. Adipocyte pseudohypoxia suppresses lipolysis and facilitates benign adipose tissue expansion. Diabetes (2014) 64(3):733-45. doi:10.2337/db14-0233
48. Floyd ZE, Kilroy G, Wu X, Gimble JM. Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1 alpha levels under normoxic conditions. J Cell Biochem (2007) 101(6):1545-57. doi:10.1002/jcb.21266
49. Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, et al. Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A (2005) 102:6207-12. doi:10.1073/pnas.0306743102
50. Morroni M, Giordano A, Zingaretti MC, Boiani R, De Matteis R, Kahn BB, et al. Reversible transdifferentiation of secretory epithelial cells into adipocytes in the mammary gland. Proc Natl Acad Sci U S A (2004) 101:16801-6. doi:10.1073/pnas.0407647101
51. Amad KH, Brennan JC, Alexander JK. The cardiac pathology of chronic exogenous obesity. Circulation (1965) 32:740-5. doi:10.1161/01.CIR.32.5.740
52. Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med (2007) 4:436-43. doi:10.1038/ncpcardio0943
53. Greenwood MR, Hirsch J. Postnatal development of adipocyte cellularity in the normal rat. J Lipid Res (1974) 15:474-83.
54. Pawlus MR, Hu CJ. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. Cell Signal (2013) 25:1895-903. doi:10.1016/j.cellsig.2013.05.018
55. Barry SP, Townsend PA. What causes a broken heart-molecular insights into heart failure. Int Rev Cell Mol Biol (2010) 284:113-79. doi:10.1016/S1937-6448(10)84003-1
56. Liu Q, Chen Y, Auger-Messier M, Molkentin JD. Interaction between NFkappaB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res (2012) 110:1077-86. doi:10.1161/CIRCRESAHA.111.260729
57. Hotamisligil GS. Inflammation and metabolic disorders. Nature (2006) 444:860-7. doi:10.1038/nature05485
58. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol (2009) 53:1925-32. doi:10.1016/j.jacc.2008.12.068
59. Lazar MA. How obesity causes diabetes: not a tall tale. Science (2005) 307:373-5. doi:10.1126/science.1104342
60. Litwin SE. The growing problem of obesity and the heart: the plot "thickens". J Am Coll Cardiol (2006) 47:617-9. doi:10.1016/j.jacc.2005.11.014
61. Walsh K. Adipokines, myokines and cardiovascular disease. Circ J (2009) 73:13-8. doi:10.1253/circj.CJ-08-0961
62. Smith HL, Willius FA. Adiposity of the heart: a clinical and pathologic study of one hundred and thirty-six obese patients. Arch Intern Med (Chic) (1933) 52:911-31. doi:10.1001/archinte.1933.00160060085007
63. Pilz B, Brasen JH, Schneider W, Luft FC. Obesity and hypertension-induced restrictive cardiomyopathy: a harbinger of things to come. Hypertension (2004) 43:911-7. doi:10.1161/01.HYP.0000126439.64838.b9